Allogene Therapeutics Receives FDA RMAT and Fast Track Designations for Cell Therapy Candidate
Shares of Allogene Therapeutics (ALLO) increased following news that its cell therapy candidate, cema-cel, received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration. The RMAT designation is reserved for therapies showing promise in treating serious or life-threatening diseases with preliminary clinical evidence of efficacy. The Fast Track status aims to expedite development and review processes, potentially leading to faster regulatory approval. These designations highlight cema-cel’s potential as a treatment option for patients suffering from severe conditions, which could accelerate its path toward market availability.
